Long-term oral administration of hop flower extracts mitigates alzheimer phenotypes in mice

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Sasaoka, Norio ^a   Sakamoto, Megumi ^a   Kanemori, Shoko ^a   Kan, Michiru ^a   Tsukano, Chihiro ^b   Takemoto, Yoshiji ^b   Kakizuka, Akira ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; GAMMA SECRETASE; HUMULUS LUPULUS EXTRACT; NOOTROPIC AGENT;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; EMOTIONAL DISORDER; ENZYME ANALYSIS; ENZYME ISOLATION; FLOWER; HUMULUS LUPULUS; IN VIVO STUDY; LONG TERM CARE; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OPEN FIELD TEST; PHENOTYPE; PROTEIN SYNTHESIS; TREATMENT DURATION; VASCULAR AMYLOIDOSIS;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; HEK293 CELLS; HUMANS; HUMULUS; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENOTYPE; PLANT EXTRACTS; SESTERTERPENES;

EID: 84900310915     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087185     Document Type: Article

References (64)

1. Wang XP, Ding HL (2008) Alzheimer's disease: epidemiology, genetics, and beyond. Neurosci Bull 24: 105-109.
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117. (Pubitemid 41797645)
3. Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, et al. (2011) Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 121: 571-587.
4. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, et al. (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366: 893-903.
5. Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, et al. (2005) A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 61: 361-368. (Pubitemid 41569310)
6. Selkoe DJ (1996) Amyloid β-protein and the genetics of Alzheimer's disease. J Biol Chem 271: 18295-18298.
7. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741.
8. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, et al. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359: 322-325.
9. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, et al. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 83: 4913-4917.
10. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356. (Pubitemid 34790756)
11. Morelli L, Perry G, Tagliavini F (2012) The contribution of the amyloid hypothesis to the understanding of Alzheimer's disease: a critical overview. Int J Alzheimers Dis 2012: 709613.
12. Neugroschl J, Sano M (2010) Current treatment and recent clinical research in Alzheimer's disease. Mt Sinai J Med 77: 3-16.
13. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, et al. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736. (Pubitemid 17054046)
14. Murrell J, Farlow M, Ghetti B, Benson MD (1991) A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 254: 97-99. (Pubitemid 21917324)
15. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704-706. (Pubitemid 21912142)
16. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, et al. (1995) Cloning of a gene bearing missense mutation in early-onset familial Alzheimer's disease. Nature 375: 754-760.
17. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, et al. (1995) A familial Alzheimer's disease locus on chromosome 1. Science 269: 970-973.
18. Selkoe DJ (2012) Preventing Alzheimer's disease. Science 337: 1488-1492.
19. Thomas P, Fenech M (2007) A review of genome mutation and Alzheimer's disease. Mutagenesis 22: 15-33. (Pubitemid 46058638)
20. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, et al. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488: 96-99.
21. Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18: 351-357. (Pubitemid 27435070)
22. Funato H, Yoshimura M, Kusui K, Tamaoka A, Ishikawa K, et al. (1998) Quantitation of amyloid b -protein (Ab) in the cortex during aging and in Alzheimer's disease. Am J Pathol 152: 1633-1640. (Pubitemid 28275021)
23. Godbolt AK, Cipolotti L, Watt H, Fox NC, Janssen JC, et al. (2004) The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort. Arch Neurol 61: 1743-1748. (Pubitemid 39463432)
24. Yamamoto Y, Hasegawa H, Tanaka K, Kakizuka A (2001) Isolation of neuronal cells with high processing activity for the Machado-Joseph disease protein. Cell Death Differ 8: 871-873. (Pubitemid 32725539)
25. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, et al. (1995) Signalling downstream of activated mammalian Notch. Nature 377: 355-358.
26. Saitou M, Narumiya S, Kakizuka A (1994) Alteration of a single amino acid residue in retinoic acid receptor causes dominant-negative phenotype. J Biol Chem 269: 19101-19107. (Pubitemid 24226232)
27. Martínez-Aguilar JF, Peña-Álvarez A (2009) Characterization of five typical agave plants used to produce mezcal through their simple lipid composition analysis by gas chromatography. J Agric Food Chem 57: 1933-1939.
28. Kumari P, Reddy CRK, Jha B (2011) Comparative evaluation and selection of a method for lipid and fatty acid extraction from macroalgae. Anal Biochem 415: 134-144.
29. Koike M, Fukushi J, Ichinohe Y, Higashimae N, Fujishiro M, et al. (2010) Valosin-containing protein (VCP) in novel feedback machinery between abnormal protein accumulation and transcriptional suppression. J Biol Chem 285: 21736-21749.
30. Mori-Konya C, Kato N, Maeda R, Yasuda K, Higashimae N, et al. (2009) p97/valosin-containing protein (VCP) is highly modulated by phosphorylation and acetylation. Genes Cells 14: 483-497.
31. Saitou M, Sugai S, Tanaka T, Shimouchi K, Fuchs E, et al. (1995) Inhibition of skin development by targeted expression of a dominant-negative retinoic acid receptor. Nature 374: 159-162.
32. Clark RF, Hutton M, Fuldner RA, Froelich S, Karran E, et al. (1995) The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet 11: 219-222.
33. Janus C (2004) Search strategies used by APP transgenic mice during navigation in the Morris water maze. Learn Mem 11: 337-346.
34. Crusio WE (2001) Genetic dissection of mouse exploratory behaviour. Behav Brain Res 125: 127-132.
35. Conrad CD, Galea LA, Kuroda Y, McEwen BS (1996) Chronic stress impairs rat spatial memory on the Y maze, and this effect is blocked by tianeptine pretreatment. Behav Neurosci 110: 1321-1334. (Pubitemid 27009196)
36. Sarnyai Z, Sibille EL, Pavlides C, Fenster RJ, McEwen BS, et al. (2000) Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proc Natl Acad Sci U S A 97: 14731-14736. (Pubitemid 32016644)
37. Nilsson LN, Arendash GW, Leighty RE, Costa DA, Low MA, et al. (2004) Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiol Aging 25: 1153-1167. (Pubitemid 39094018)
38. Vom Berg J, Prokop S, Miller KR, Obst J, Kälin RE, et al. (2012) Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 18: 1812-1819.
39. Sato K, Higuchi M, Iwata N, Saido TC, Sasamoto K (2004) Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur J Med Chem 39: 573-578. (Pubitemid 38962492)
40. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, et al. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76: 173-181. (Pubitemid 32044380)
41. Kimberly WT, Zheng JB, Guénette SY, Selkoe DJ (2001) The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem 276: 40288-40292.
42. Selkoe DJ (2002) Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest 110: 1375-1381.
43. Lu YH, Wei BL, Ko HH, Lin CN (2008) DNA strand-scission by phloroglucinols and lignans from heartwood of Garcinia subelliptica Merr. and Justicia plants. Phytochemistry 69: 225-233.
44. Viswanathan A, Greenberg SM (2011) Cerebral amyloid angiopathy in the elderly. Ann Neurol 70: 871-880.
45. Wang B, Yang W, Wen W, Sun J, Su B, et al. (2010) γ-secretase gene mutations in familial acne inversa. Science 330: 1065.
46. Kelleher RJ 3rd, Shen J (2010) γ-secretase and human disease. Science 330: 1055-1056.
47. Xia X, Qian S, Soriano S, Wu Y, Fletcher AM, et al. (2001) Loss of presenilin 1 is associated with enhanced β-catenin signaling and skin tumorigenesis. Proc Natl Acad Sci U S A 98:10863-10868. (Pubitemid 32878710)
48. Extance A (2010) Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 9: 749-751.
49. Okochi M, Tagami S, Yanagida K, Takami M, Kodama TS, et al. (2013) γ-secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43. Cell Rep 3: 42-51.
50. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, et al. (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69: 1002-1010.
51. Delrieu J, Ousset PJ, Caillaud C, Vellas B (2012) 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem 120: 186-193.
52. von Bernhardi R (2010) Immunotherapy in Alzheimer's disease: where do we stand? Where should we go? J Alzheimers Dis 19: 405-421.
53. Li T, Wen H, Brayton C, Laird FM, Ma G, et al. (2007) Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci 27: 10849-10859. (Pubitemid 47535873)
54. Akazawa H, Kohno H, Tokuda H, Suzuki N, Yasukawa K, et al. (2012) Anti-inflammatory and anti-tumor-promoting effects of 5-deprenyllupulonol C and other compounds from Hop (Humulus lupulus L.). Chem Biodivers 9: 1045-1054.
55. Choi Y, van Breemen RB (2008) Development of a screening assay for ligands to the estrogen receptor based on magnetic microparticles and LC-MS. Comb Chem High Throughput Screen 11: 1-6.
56. Chadwick LR, Pauli GF, Farnsworth NR (2006) The pharmacognosy of Humulus lupulus L. (hops) with an emphasis on estrogenic properties. Phytomedicine 13: 119-131. (Pubitemid 41799601)
57. Desai A, Darland G, Bland JS, Tripp ML, Konda VR (2012) META060 attenuates TNF-α-activated inflammation, endothelial-monocyte interactions, and matrix metalloproteinase-9 expression, and inhibits NF-κB and AP-1 in THP-1 monocytes. Atherosclerosis 223: 130-136.
58. Prasad S, Sung B, Aggarwal BB (2012) Age-associated chronic diseases require age-old medicine: role of chronic inflammation. Prev Med 54: S29-37.
59. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421. (Pubitemid 30349107)
60. Levine AJ, Battista M (2004) Estrogen replacement therapy: effects on the cognitive functioning and clinical course of women with Alzheimer's disease. Arch Clin Neuropsychol 19: 769-778. (Pubitemid 39013342)
61. Wharton W, Baker LD, Gleason CE, Dowling M, Barnet JH, et al. (2011) Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. J Alzheimers Dis 26: 495-505.
62. Erkkola R, Vervarcke S, Vansteelandt S, Rompotti P, De Keukeleire D, et al. (2010) A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts. Phytomedicine 17: 389-396.
63. Van Cleemput M, Cattoor K, De Bosscher K, Haegeman G, De Keukeleire D, et al. (2009) Hop (Humulus lupulus)-derived bitter acids as multipotent bioactive compounds. J Nat Prod 72: 1220-1230.
64. Heyerick A, Vervarcke S, Depypere H, Bracke M, De Keukeleire D (2006) A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas 54: 164-175.